NAFLD Clinical Trial
Official title:
A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men
Using a small Randomized Controlled Trial (RCT) study design, PNPLA3 risk allele carriers (CG/GG genotype) with NAFLD, will be assigned 2:1 to a tailored NAFLD-specific weight loss intervention compared to a wait-list control group.
The Mexican-American population accounts for 64.3% of the U.S. Hispanic population and is the fastest growing Hispanic subgroup. Non-alcoholic fatty liver disease (NAFLD) is a chronic disease associated with obesity that is highest in the nation for Mexican-American men. NAFLD consists of a spectrum of conditions, ranging from fatty liver to cirrhosis and liver cancer. Lack of physical activity and sugar-sweetened beverage consumption are risk factors for NAFLD and are highly evident in the Mexican-American male population. Additionally, Mexican-American men are at increased risk of NAFLD and liver cancer if they are carriers of a version of a gene (PNPLA3) found to increase risk and severity of NAFLD. In the absence of prescription medications, weight loss due to changes in diet and physical activity is recommended for the prevention and treatment of NAFLD. Changes in lifestyle that result in >5% body weight loss have been shown to improve levels of liver fat and even reverse the condition. Despite the clear need to develop effective intervention strategies for Mexican-American men, no studies to date have explored the use of health risk assessment strategies, including genetic risk, to motivate behavior change to reduce the risk of NAFLD in Mexican-American men. Consequently, this will be the first weight loss intervention for Mexican-American men to incorporate genetic predisposition and lifestyle risk factors of NAFLD (e.g., dietary sugar consumption), as a strategy to improve engagement in weight loss and weight maintenance behaviors. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06101433 -
The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A
|
N/A | |
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Active, not recruiting |
NCT05479721 -
LITMUS Imaging Study
|
||
Completed |
NCT05527938 -
Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children
|
N/A | |
Recruiting |
NCT06308757 -
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
|
N/A | |
Completed |
NCT02654977 -
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
|
Phase 2 | |
Completed |
NCT02927184 -
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT06047847 -
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
|
N/A | |
Active, not recruiting |
NCT03534908 -
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
|
||
Recruiting |
NCT06098417 -
Biomarkers in the Diagnosis and Prognosis of NAFLD
|
||
Recruiting |
NCT04564391 -
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
|
N/A | |
Not yet recruiting |
NCT05984745 -
Effect of CoQ10 on the Outcome of MAFLD Patients
|
Phase 2 | |
Not yet recruiting |
NCT05052515 -
The Effects of Natural Extracts Supplementation on NASH Patients
|
N/A | |
Recruiting |
NCT02459496 -
Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus
|
N/A | |
Completed |
NCT01936779 -
Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans
|
N/A | |
Completed |
NCT05844137 -
Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04664036 -
Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus
|
||
Recruiting |
NCT04976283 -
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
|
Phase 4 | |
Recruiting |
NCT03587298 -
Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
|
||
Completed |
NCT02952170 -
Impact of Weight Loss Surgery in Adolescents With NAFLD
|
N/A |